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Abstract 
Proteinaceous inclusions, called Lewy bodies, are used as a pathological hallmark for 
Parkinson’s disease (PD). Lewy bodies contain insoluble α-synuclein (aSyn) and many other 
ubiquitinated proteins, suggesting a role for protein degradation system failure in the PD 
pathogenesis. Indeed, proteasomal dysfunction has been linked to PD but commonly used in 
vivo toxin models, such as 6-OHDA or MPTP, do not have a significant effect on the 
proteasomal system or protein aggregation. Therefore, we wanted to study the characteristics 
of a proteasomal inhibitor, lactacystin, as a PD model on young and adult mice.  
To study this, we performed stereotactic microinjection of lactacystin above the substantia nigra 
pars compacta in young (2 month old) and adult (12-14 month old) C57Bl/6 mice. Motor 
behavior was measured by locomotor activity and cylinder tests, and the markers of 
neuroinflammation, aSyn and dopaminergic system were assessed by immunohistochemistry 
and HPLC.  
We found that lactacystin induced a Parkinson’s disease-like motor phenotype 5-7 days after 
injection in young and adult mice, and this was associated with wide-spread neuroinflammation 
based on glial cell markers, aSyn accumulation in substantia nigra, striatal dopamine decrease 
and loss of dopaminergic cell bodies in the substantia nigra and terminals in the striatum. When 
comparing young and adult mice, adult mice were more sensitive for dopaminergic 
degeneration after lactacystin injection that further supports the use of adult mice instead of 
young when modelling neurodegeneration. Our data showed that lactacystin is useful in 
modeling various aspects of Parkinson’s disease, and taken together, our findings emphasize 
the role of a protein degradation deficit in Parkinson’s disease pathology, and support the use 
of proteasomal inhibitors as Parkinson’s disease models. 
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Introduction  
Parkinson’s disease (PD) is the second most common neurodegenerative disease, with an 
incidence of 1-2% of people over 65 years old. In PD, dopaminergic neurons in the substantia 
nigra pars compacta (SNc) degenerate, leading to typical clinical findings such as tremor, 
rigidity and bradykinesia due to lack of dopamine in the striatum. Common neuropathological 
findings of PD are insoluble inclusions, Lewy bodies, mainly consisting of an α-synuclein 
(aSyn) protein (Spillantini et al. 1998). Although appearance of Lewy bodies is considered a 
hallmark for PD, it appears that fibrillary forms of aSyn that are formed during the aggregation 
process are the toxic species and may be associated with neuronal loss in the SNc (Winner et 
al. 2011). Current drug therapies are mostly based on dopamine replacement that only relieves 
the symptoms of PD but are not curative and cannot stop or delay the progress of the disease. 
Therefore, it is important to develop novel drug therapies and drug candidates, and for this, 
tools for preclinical studies are needed.  
The challenge of generating a mouse model of PD is to find a model that would recapitulate all 
pathophysiological aspects of the disease: gradual dopaminergic neurodegeneration in the 
nigrostriatal tract, aSyn-containing protein aggregate formation, motor behavioral deficits and 
neuroinflammation. Neurotoxin models, 6-OHDA and MPTP, are conventionally used as PD 
models that show the gradual dopaminergic neurodegeneration and behavioral deficits but 6-
OHDA fails to produce substantial protein accumulation in the brain and MPTP administration 
induces non-fibrillar aggregate formation only after extended administration (Meredith et al. 
2002; Fornai et al. 2005; Jin et al. 2005). After revealing that non-soluble aSyn is one of the 
main components of Lewy bodies (Spillantini et al. 1998) it has been of huge interest to study 
its role in PD, where it indisputably has a role in the pathogenesis. Since toxin models do not 
easily produce aSyn-rich protein inclusions, several models that are based on either transgenic 
or viral vector-mediated overexpression of aSyn have been published  (Kahle et al. 2001; 
Matsuoka et al. 2001; Tofaris et al. 2006; St Martin et al. 2007; Ulusoy et al. 2010; Decressac 
et al. 2012). Within the models, there is a wide variation of the degree of neuronal degeneration 
and protein accumulation, and motor behavioral phenotype of these mice is often weak or not 
present. Very recently, it was shown that when human aSyn is expressed in a mouse carrying 
normal mouse aSyn, aSyn aggregation is limited compared to overexpressing human aSyn 
without mouse aSyn homologue (Fares et al. 2016). This finding suggests that synuclein 
homologs reduce aggregation of each other and offers an explanation on why less toxicity is 
seen in many transgenic models regardless of high expression. 
 Although aSyn and its neurotoxic species, oligomers (Winner et al. 2011), have raised lots of 
interest in PD research, there are also several other proteins that are present in the Lewy bodies 
such as ubiquitin and other proteasomal proteins pointing to a role of a failure of protein 
clearance systems in the pathophysiology of neurodegeneration. Protein accumulation and 
aggregation may be facilitated by disturbances in cellular clearance and processing pathways, 
such as ubiquitin-proteasome (UPS) and autophagy-lysosome systems (Ebrahimi-Fakhari et al. 
2012). Importantly, UPS dysfunctions have been linked to PD; decreased proteasomal activity 
has been identified in the SNc of PD patients (McNaught and Jenner 2001; McNaught et al. 
2003; Tofaris et al. 2003), and genetic mutations in an ubiquitin ligase, parkin, have been linked 
to early-onset Parkinsonism (Kitada et al. 1998). Various forms of aSyn have also been shown 
to compromise its own proteasomal clearance, thus promoting its accumulation (Snyder et al. 
2003; Pan et al. 2008a; Ebrahimi-Fakhari et al. 2011). Furthermore, aSyn has been shown to 
inhibit proteasomal function (Ebrahimi-Fakhari et al. 2011) and A30P or A53T point mutated 
aSyn also inhibits chaperone-mediated autophagy (Cuervo et al. 2004), thus inducing their own 
accumulation and buildup of other proteins. It still remains to be clarified at what point of the 
aggregate formation process the protein clearance systems start to decline — at the onset or 
after protein already accumulates.  
A more recent approach to model PD in vivo has been to use lactacystin (LC), a selective 
proteasome inhibitor (Fenteany and Schreiber 1998). It has been successfully used in rats and 
mice and it appears that the nigral administration produces a fast-onset PD-like phenotype, 
including aSyn accumulation, tyrosine hydroxylase (TH) positive cell loss and behavioral 
deficits (McNaught et al. 2002; Pan et al. 2008b; Lorenc-Koci et al. 2011; Bentea et al. 2015). 
Since ageing is one of the key predisposing factors to developing PD or other neurodegenerative 
diseases, we further characterized the nigral LC injection as a mouse PD model using young 
and adult mice. Furthermore, we wanted to study the neuroinflammatory responses in this 
model, because they have not been thoroughly investigated in previous models. We have also 
analysed the key elements of a PD model: motor behavior, dopamine cell loss, and aSyn 
accumulation after LC administration. In addition, to further characterizing the model, we 
studied the expression of gamma-Aminobutyric acid (GABA) markers since increase of 
GABAergic neurotransmission after the decrease in inhibitory dopaminergic neurons has been 
described in PD models (Salin et al. 2002; Wang et al. 2010) 
 
 
 Experimental procedures 
 
Chemicals 
Chemicals used were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise 
specified. Ethanol was purchased from Altia (Helsinki, Finland). LC was purchased from A.G. 
Scientific (#L-1147; San Diego, CA, USA) and dissolved in PBS in concentration of 2 mg/ml. 
LC solution was protected from light.  
 
Animals 
Male C57Bl/6RccHsd mice were obtained from Harlan Laboratories. Mice that were 8-9 weeks 
(young) and 12-14 months (adult) old were used for the experiments The animals were 
maintained at 20-22 °C room temperature with 12:12 h light:dark rhythm and had ad libitum 
access to food and water. The experiments were carried out according to the European 
Community guidelines for the use of experimental animals and approved by the Finnish 
National Board of Animal Experiments (ESAVI/198/04.10.07/2014).  
 
Stereotactic microinjection and drug treatments 
The mice were deeply anaesthetized (Univentor anaesthesia unit, Zejtun, Malta) with 2-4 % 
isoflurane (Baxter, Deerfield, IL, USA) and placed on a stereotactic frame (Stoelting, Wood 
Dale, IL, US) for injection of 2 µg of LC above the SNc. A 1 μl injection of LC was delivered 
with a 10 μl –microsyringe (World Precision Instruments, Sarasota, FL, USA) connected to an 
injector (Quintessential stereotaxic injector, Stoelting) at 0.2 μl/min on the right side of the 
brain to the following coordinates: A/P -3.2; M/L -1.2 ; D/V -4.3 from the bregma according to 
(Franklin and Paxinos 1997), and the needle was left in place for 5 minutes after injection until 
it was slowly withdrawn. Mice received subcutaneous buprenorphine 0.05 mg/kg (Temgesic, 
Reckit Benckiser Healthcare Ltd, Slough, UK) for post-operative pain relief, and lidocaine 
(Orion Pharma, Espoo, Finland) was used as a local anesthetic during the operation. Number 
of animals injected was: Young mice n=10 LC injected and n=8 PBS injected (vehicle) for 
immunohistochemistry and behavioral analysis, and a separate cohort of n=7 for HPLC 
analysis; adult mice n=3 LC injected and n=4 vehicle injected. Since we wanted to characterize 
the fast-onset effects of LC injection, and a previous study (Bentea et al. 2015) reported the 
mice having the most disturbances in their motor behavior 1 week post-injection, the mice were 
 sacrificed on the 10th day post injection.  
 
Cylinder test  
The cylinder test to evaluate forelimb use asymmetry was performed as described previously 
(Schallert et al. 2000). More specifically, the mice were removed from their home cage and 
placed in a plexiglass cylinder (diameter 12 cm, height 15 cm) that rested on a clear plastic 
platform. A video camera was placed directly underneath the cylinder and each mouse was 
recorded for 5 min, and then returned to its home cage. Animals were scored by an observer 
blind to the treatments. The number of touches for each ipsilateral, contralateral, and 
simultaneous paw placement were recorded. The test was done on the 8th day after LC or PBS 
microinjection. The contralateral paw use preference was calculated using the following 
equation: (contralateral paw contacts + 0.5 x both paw contacts) / (ipsilateral + contralateral + 
both paw contacts). The number of animals was 8 in vehicle and 10 in LC group in young 
animals, and 4 in vehicle and 3 in LC group adult animals. 
 
Horizontal and vertical activity 
The horizontal and vertical activity was tested as described in (Mijatovic et al. 2007) to evaluate 
the effect of LC lesion on the spontaneous locomotor activity. Measurement was performed on 
the 9th day after injection. Mice were placed in transparent cages (25 cm × 25 cm × 15 cm) in 
the activity monitor measuring infrared beam interruptions (MED Associates, St. Albans, GA, 
USA). Due the short length of the experiment, no food or water was placed to cages. The 
measurement was started right after mice were placed in the cages and the data was collected 
at 15 min intervals for 2 h. The number of animals was 8 in vehicle and 10 in LC group in 
young animals, and 4 in vehicle and 3 in LC group adult animals. 
 
Tissue dissection 
On the 10th day after LC or PBS microinjection, mice were deeply anesthetized with sodium 
pentobarbital (150 mg/kg, i.p.) and transcardially perfused first with phosphate-buffered saline 
(PBS) to remove blood and then with 4 % paraformaldehyde (in PBS) to fix the tissue for 
immunohistochemistry. Brains were removed and immersed in 4 % paraformaldehyde 
overnight to fix the tissue. The brains were then immersed first in 10 % sucrose solution (in 
PBS) for overnight following with 30 % sucrose solution, kept in +4°C until they sank, after 
which the samples were quickly frozen with isopentane on dry ice and stored at -80 °C until 
 sectioning. Brains were sectioned at 30 µm thickness. Floating sections were stored in -20 °C. 
For high-pressure liquid chromatograph (HPLC), striatal samples were quickly dissected from 
fresh brain tissue after PBS perfusion and frozen at -80 °C until homogenization (described in 
Mijatovic et al. 2011). 
 
Immunohistochemistry  
For the analysis of brain aSyn, glutamic acid decarboxylase 65/67 (GAD), tyrosine hydroxylase 
(TH), and glial cell markers (glial fibrillary acidic protein; GFAP and ionized calcium-binding 
adapter molecule; Iba1), immunohistochemistry was performed as described in (Mijatovic et 
al. 2007; Myohanen et al. 2012). In brief, the endogenous peroxidase activity was inactivated 
with 10% methanol and 3% H2O2 in PBS (pH 7.4) for 10 min (not in immunofluorescence 
staining), and non-specific binding was blocked with 10% normal donkey serum (aSyn, Iba1) 
(#S30, Millipore, Temencula, CA, USA) or 10% normal goat serum (TH, GAD, GFAP, Iba1, 
Ubiquitin) (#S-1000, Vector Laboratories, Burlingame, CA, USA) or 10% normal rabbit serum 
(GFAP-IFL) (#S-5000, Vector Laboratories) in PBS containing 0.5 % Triton-X-100. The 
sections were incubated overnight at room temperature with primary antibodies in 1% normal 
serum in PBS (see details in Table 1) followed by washing with PBS. The sections were then 
incubated with the following secondary antibodies, depending on primary antibody; donkey 
anti-sheep HRP conjugated secondary antibody (aSyn) (1:500, #ab6900, Abcam), goat anti-
rabbit HRP conjugated secondary antibody (GAD) (1:500, #31460, Thermo Scientific, 
Rockford, USA), goat anti-rabbit biotinylated secondary antibody (TH, GFAP and Iba1; 1:500, 
BA1000, Vector Laboratories), goat anti-rabbit Texas Red conjugated (ubiquitin) (1:200, #T-
2767, Thermo Scientific), rabbit anti-chicken fluorescein conjugated (GFAP-IFL) (1:300, 
#31501, Thermo Scientific) or donkey anti-goat Alexa Fluor 488 conjugated (Iba1-IFL) 
antibodies (1:200, ab150129, Abcam). The signal for TH, GFAP and Iba1 staining was 
enhanced with the avidin-biotin complex –method (Vectastain® ABC kit standard, #PK-4000, 
Vector Laboratories). The antigen-antibody complexes were visualized following incubation 
with 0.05% 3,3'-diaminobenzidine and 0.03% hydrogen peroxide solution. Finally, the DAB-
stained sections were moved to objective glass, dehydrated in alcohol series and mounted with 
Depex (BDH, Poole, UK). Fluorescently labeled sections were mounted with Vectashield (H-
1200, Vector Laboratories) 
 
Stereological counting and optical density analysis 
The number of TH-positive neurons in the SNc was analyzed by a person blinded to the 
 treatment groups. Three sections from each animal were selected (every 6th section). 
StereoInvestigator (MBF Bioscience, USA) was used for the stereological analysis. TH-
positive cells were counted at predetermined intervals (x = 100 μm, y = 80 μm) within the 
counting frame (60 μm × 60 μm) superimposed on the image using a 60× oil objective 
(Olympus BX51, Olympus Optical, Japan) equipped with an Optronics camera.  
For optical density (OD) analysis of aSyn, TH and GAD, immunohistochemically stained brain 
sections were imaged using 3DHISTECH slide scanner (3DHISTECH Ltd., Budabest, 
Hungary) at the service provided in the Institute of Biotechnology, University of Helsinki. ODs 
were analysed using ImageJ (NIH, Bethesda, MD, USA). Images were converted into grayscale 
and inverted before analysis. Area to be analyzed was selected using the freehand selection –
tool. The background staining values of each brain area were subtracted from raw data values 
of the same brain area.  
Neuroinflammation in the brain was semi-quantitatively analyzed using Image Pro Plus 6 
software (Media Cybernetics, Rockville, MD, USA). Briefly, images of brain sections that were 
exported from 3DHISTECH were converted into grayscale and inverted. Then pre-determined 
area was analyzed from the substantia nigra (SN) injection side and control side. To estimate 
area stained in the striatum, a circular annotation was drawn over the area and same sized 
regions were analyzed from both sides. Area stained in the selected regions were counted using 
count and measure objects tool.  
Number of animals in aSyn, TH and GAD analysis was 4 in vehicle group and 8 in LC group 
(young) and 4 in vehicle and 3 in LC group (adult). In glial cell markers, the number of animals 
was 3 in vehicle and 3 in LC group in both age groups. Altogether 3-4 samples of each brain 
area/staining per animal per group were analyzed. OD values for each mouse were calculated 
as OD injection side / OD intact side x 100 %. Image panels were prepared by Adobe Photoshop 
CS6 software (version 13.0, Adobe Systems, San Jose, CA, USA). 
 
Confocal microscopy 
Fluorescent double-labeled sections were photographed using an upright microscope (Leica 
DM5000B, Leica Microsystems Inc.) with broadband laser confocal device (Leica TCS SP5, 
Leica Microsystems Inc.). After the images were captured with an imaging device, confocal 
double-labeled immunofluorescence micrographs were merged to detect colocalization by 
using Adobe Photoshop CS6 software (Adobe Systems). Only corrections to brightness and 
contrast were made. 
  
Analysis of neurotransmitters and metabolites 
The striatal brain tissue samples were homogenized as described earlier (Airavaara et al. 2006). 
Briefly, the striatal samples were homogenized in 0.5 ml of homogenization solution (0.2 M 
HClO4 and antioxidant solution). The homogenates were centrifuged at 20,800g for 35 min at 
4 C̊. Supernatant was removed to 0.5 ml Vivaspin ﬁlter concentrators (10,000 MWCO PES; 
Vivascience AG, Hannover, Germany) and centrifuged at 8,600g at 4 ̊C for 35 min. The tissue 
concentrations of dopamine, its main metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) 
and homovanillic acid (HVA), and serotonin (5-HT) and its metabolite 5-hydroxyindoleacetic 
acid (5-HIAA) were analyzed with a HPLC equipped with an electrochemical detector. 
Concentrations are calculated as nanograms per milligram of brain tissue. Number of animals 
was 7 in both treatment groups. 
 
Statistics 
Statistical analysis was done using GraphPad Prism 5 and 6 softwares. Student’s t-test, 1-way 
ANOVA with Newman-Keuls multiple comparisons or 2-way ANOVA with Tukey’s multiple 
comparisons test were used. Data is presented as Mean ± SEM and F-values are included with 
statistics. 
 
 
Results 
 
Motor impairment after LC administration  
To evaluate the degree of LC-induced unilateral lesion in the nigrostriatal tract we measured 
horizontal and vertical locomotor activity as well as assessed the ipsilateral and contralateral 
limb use with cylinder test in mice. Additionally, we observed spontaneous contralateral 
rotating behavior in LC-injected mice of both age groups starting and being the strongest 2 to 
3 days after the injection and continuing to the end of the experiment but this was not 
quantitatively analyzed. 
 
Cylinder test 
The paw use preference during rearing was measured with cylinder test. LC groups had reduced 
use of contralateral paw 8 days after lesioning pointing to unilateral damage of nigrostriatal 
 tract (Fig 1E-F; t = 2.751, df = 16; P = 0.0142 and Adult: t = 2.390, df = 5; P = 0.0624, Student’s 
t-test).  
 
Horizontal and vertical activity  
Locomotor activity was measured for 2 h on the 9th day after LC lesioning. LC showed a trend 
to reduce total distance travelled (Fig 1A; Young: t = 1.776; df = 16; P = 0.0948, Student’s t-
test) and vertical counts (Fig 1B; t = 1.941, df = 16; P = 0.0701, Student’s t-test) in young mice. 
In adult animals, there were no alterations in distance travelled or vertical activity, although the 
trend in distance travelled was opposite to young mice (Fig. 1C-D; t = 0.9442, df = 5; P = 0.3884 
and t = 0.047, df = 5; P = 0.9643 respectively, Student’s t-test).  However, the number of animals 
in adult mice groups (3 and 4) is not sufficient to achieve statistically reliable results in 
behavioral tests, and therefore, these results cannot be considered conclusive.  
  
Fig. 1A-F: The behavioral assessment of mice after unilateral nigral lactacystin (LC) 
lesioning by cylinder and locomotor activity tests. The paw use preference for rearing 8 days 
after LC injection was measured by cylinder test. Both LC groups showed decreased use of 
contralateral paw (Young mice: P = 0.0142) although insignificantly in adult mice (ns, P = 
0.0624) (A-B). Horizontal and vertical activity was measured for 2 h 9 days after LC (2 µg) 
injection. Stereotactic injection of PBS was used as a sham control. In young, 8-9 weeks old 
mice, LC shows a trend to decrease total distance travelled (ns, P = 0.0948) (C) and vertical 
counts (ns, P = 0.0701) (D). In adult mice, no effect was seen in the locomotor activity (E-F).  
* P < 0.05; unpaired Student’s t-test was used as statistical analysis in all experiments; n=10 
LC injected and 8 vehicle in young mice, n= 3 LC injected and 4 vehicle in adult mice. 
 
Reduction of markers of nigrostriatal dopamine system after LC injection  
 In the SNc, LC induced approx. 40% TH-positive neuron loss in young mice and 50% decrease 
in adult mice (Fig 2D-F; Young: t = 3.432, df = 10; P = 0.0064; Fig 2J-L; Adult: t = 2.358, df 
= 5;   P = 0.0649). TH positive neurons remaining in the LC-lesioned side compared to the 
unlesioned side of the SNc were 64.9 ± 5.4 % in the young and 62.6 ± 15.52 in the adult mice 
(Fig 2F and L). LC significantly decreased striatal TH OD (Fig 2A-C; Young: t = 4.412, df = 
9; P = 0.0017; Fig 2G-H; Adult: t = 3.620, df = 5; P = 0.0152, Student’s t-test) and TH loss was 
significantly greater in the adult mice; the remaining amount of TH-positive terminals in the 
lesion side compared to control side was 61.39 ±10.7 % in adult and 80.1 ± 2.8 % in young 
mice (Fig 2C and I). This was also observed in 2-way ANOVA analysis (Fig. 2M) where LC 
had a significant effect on striatal TH (P<0.0001; F(1,14) = 33.76, 2-way ANOVA) and there 
was also an interaction with the age of the mice (P = 0.0432; F(1,14) = 4.944, interaction 
(LC*age), 2-way ANOVA).  
Striatal dopamine levels were measured only from the young mice after LC lesion. LC injection 
above the SN decreased the level of striatal dopamine by approximately 55 % (Fig 2N; t = 
3.581, df = 12; P = 0.0038) and its metabolite DOPAC (Fig 2N; t = 2.737, df = 12; P = 0.0180) 
compared to intact side. The levels of HVA were not significantly altered (Fig 2N; t = 0.5983, 
df = 12; P = 0.5608). LC did not affect 5-HT or 5-HIAA levels (See supplementary materials 
S1).  
  
Fig. 2A-M. Tyrosine hydroxylase (TH) positive neuron loss and reduced striatal dopamine 
(DA) and metabolite content after lactacystin (LC) lesion. LC administered supranigrally 
significantly decreased TH optical density (OD) in the striatum of young (8-9 weeks old, A-C), 
and in the striatum of adult mice (12-14 months old, G-I). The interaction between striatal TH 
decrease and age and LC injection was also observed in 2-way ANOVA analysis (M; P<0.0001 
LC; P = 0.0432 interaction (age*LC), 2-way ANOVA).  In the substantia nigra pars compacta 
(SNc) the cell loss was at the same level in both age groups (Young D-F; Adult J-L, P = 0.06 
in adult mice). In the young mice, 10 days after LC injection significant depletion of the striatal 
DA (N) and 3,4-dihydroxyphenylacetic acid (DOPAC) levels were observed. However, no 
significant decrease was seen in the homovanillic acid (HVA) levels. * P < 0.05, ** P < 0.01; 
unpaired Student’s t-test was used as statistical analysis in all experiments; n=8 LC injected 
 and 4 vehicle in young mice, n=3 LC injected and 4 vehicle in adult mice; n=7 in both groups 
in HPLC assays. 
 
LC-induced glial cell activation and accumulation of ubiquitinated proteins 
in glial cells 
Lactacystin induced strong and widespread astroglial cell activation. Intense GFAP 
immunoreactivity was seen throughout the whole injected hemisphere at the SN level (anterior-
posterior) after lactacystin injection compared to PBS and to uninjected side  (Fig 3A-B, Q, P 
= 0.0003; F(3,11) = 23.20, P<0.001 Newman-Keuls post-hoc test, 1-way ANOVA). Lactacystin 
also increased the expression of ubiquitinated proteins in GFAP positive cells that was not seen 
in such high amounts in the control side (Fig. 4A-L) or after PBS injection (Supplementary Fig. 
S2). Although we saw an increased GFAP activation around the lactacystin-injected brain 
hemisphere in adult mice (Fig. 3C-D), due to large variance in our small sample group the data 
did not reach significance in the statistical assay. Moreover, astroglial activation was also seen 
in the striatum, particularly in adult mice (Fig 3E-F, R; Young: lactacystin vs. PBS; P = 0.0150; 
F(3,11) = 6.563, P<0.01, intact vs lactacystin; P<0.05; Adult: lactacystin vs. PBS; P = 0.0054; 
F(3,11) = 9.378, P<0.01 Newman-Keuls post-hoc test, 1-way ANOVA) but not in the cortical 
brain structures of the injected side. 
In addition to astroglial activation, microglial cells detected by Iba1 were intensively activated 
in the SN level after LC injection (Fig 3I-J, S; Young: intact vs LC; P = 0.0002; F(1,8)=39.88, 
P<0.01; Fig 3K-L, V; Adult: LC vs. PBS P = 0.0014 F(1,8)=22.56, P<0.01, intact vs LC P = 
0.0092; F(1,8)=11.64, P<0.01 Tukey’s post-hoc test, 2-way ANOVA). Similar to astroglial 
cells, microglial cell activation was widespread, covering the whole LC-injected brain 
hemisphere at the level of injection (anterior-posterior) in both young and adult mice (Fig 3M-
P). In addition, similar accumulation of ubiquitinated proteins as in GFAP positive astroglial 
cells were seen in microglial cells in double-label immunofluorescence (Fig. 4M-X). No 
difference in activation of microglial cells was observed in the striatum.  
  
Fig. 3A-V. The effects of lactacystin (LC) on GFAP and Iba1 immunoreactivity. LC 
microinjection above the substantia nigra induced widespread activation of astroglial cells 
around the hemisphere of injection side at nigral level, that were detected by glial fibrillary 
acidic protein (GFAP) staining (Young, A-B, Q; Adult, C-D, T). GFAP immunostaining was 
also seen in the striatum after LC injection and it was particularly intense in adult mice (Young, 
E-F, R; Adult, G-H, U). Similar to GFAP, microglial cells were significantly activated in LC 
 injected side (ionized calcium-binding adapter molecule (Iba1); Young, I-J, M-N, S; Adult, K-
L, O-P, V). Young mice 8-9 weeks old, Adult mice 12-14 months old. Scale bar is 100 µm. * 
P < 0.05, ** P < 0.01, P < 0.001, vs. intact, # P < 0.05, ## P< 0.01, ### P < 0.001 vs. PBS 
injection; GFAP: Newman-Keuls post-hoc test, 1-way ANOVA; Iba1: Tukeys’s post-hoc test, 
2-way ANOVA; n=3 in all groups. 
 
 
Fig. 4A-X. Accumulation of ubiquitin-labelled proteins in astroglial and microglial cells 
after lactacystin injection. Ubiquitin-immunostained (UbiQ) cells were generally decreased 
in LC injected side of the substantia nigra (B, N) compared to intact side (E, Q). Increased 
colocalization between UbiQ and GFAP was seen after LC injection (G-I), and similar staining 
was seen between UbiQ and Iba1 (S-U). In intact side, less colocalization was seen with UbiQ 
both in GFAP and Iba1-labelled cells (J-L, V-X). White arrows are pointing to the 
colocalization. Scale bar is 50 µm in A-F and M-R, and 5 µm in G-L and S-X. 
 
LC induces aSyn accumulation in the substantia nigra 
LC produced robust accumulation of aSyn in the SN compared to PBS control group (Fig 5A-
C and E-G; Young: df = 14; P = 0.0012; Adult: t = 3.161, df = 5; P = 0.0251, Student’s t-test). 
Accumulation percentages for young mice are 105.4 ± 5.1 for PBS, 169.3 ± 20 for LC and for 
adult mice 104.8 ± 16.9 vs. 185.7 ± 19.2 (Fig 5C and G). The accumulation was observed both 
in the SNc and SN pars reticulata (SNr). We did not observe a significant increase of aSyn in 
the striatum after LC (Fig 5D and H). 
 
  
Fig. 5A-H. Accumulation of α-synuclein (aSyn) in SN after lactacystin (LC) injection. 
Representative images of nigral aSyn immunostaining 10 days after nigral stereotaxic injection 
of PBS and LC in young (A-B) and adult (E-F) mouse. LC produced robust accumulation of 
aSyn in the substantia nigra (SN) compared to PBS control group (young mouse; C, P < 0.01; 
adult mouse; G, P < 0.05) However, significant accumulation of aSyn in the striatum was not 
detected in both groups (D, H).  * P < 0.05, ** P < 0.01, unpaired Student’s t-test; n=8 LC 
injected and 8 vehicle in young mice, n=3 LC injected and 4 vehicle in adult mice. 
 
LC induces increase in GAD in SNr 
As we observed aSyn accumulation in the SNr, we also wanted to study the expression of GAD, 
a GABA synthesising enzyme. We saw accumulation of GAD in the SNr after LC lesioning in 
young mice 142.3 ± 6.6 % compared to PBS control 103.8 ± 2.1 % and in adult mice 150 ± 8.5 
% compared to 98.5 ± 5.9 % (Fig 6A-C, Young: t = 5.094, df = 14; P = 0.0001; D-F, Adult: t = 
5.180, df = 5; P = 0.0035; Student’s t-test). 
 
Fig. 6A-F. Accumulation of glutamic acid decarboxylase 65/67 (GAD) in the SN pars 
reticulata (SNr) after lactacystin (LC) lesioning. In both age groups (Young 8-9 weeks old 
(A-C), adult 12-14 months old (D-F)) significant accumulation GABA synthesising enzyme, 
GAD, was observed compared to sham lesion control (young mouse; C, P < 0.001; adult mouse; 
F, P < 0.01). ** P < 0.01, *** P < 0.001, unpaired Student’s t-test; n=8 LC injected and 8 
vehicle in young mice, n=3 LC injected and 4 vehicle in adult mice. 
 Discussion 
In this study, we have characterized a mouse model of PD that is based on direct proteasomal 
inhibition in the SN of young and adult mice. Although LC has been used as a PD model in 
earlier studies either by injecting it into the medial forebrain bundle or striatum (Fornai et al. 
2003; Vernon et al. 2011; Shen et al. 2013; Konieczny et al. 2014a), and recently in mouse 
(Bentea et al. 2015; Kumar et al. 2015) and rat (Konieczny et al. 2014b; Harrison et al. 2015; 
Pienaar et al. 2015) SN, to our knowledge this is the first time when LC injection has also been 
used in adult mice and wide-spread neuroinflammation has been observed and thoroughly 
analyzed. The model shows several well-established features of PD – motor deficits, 
nigrostriatal dopamine loss and aSyn accumulation as the most important, and we indeed 
detected differences in response between young and adult mice. However, the number of adult 
mice in the current study was low and this should be kept in mind when drawing conclusions 
based on our results. 
Young LC-injected mice showed hypolocomotion in 2 h locomotor activity test and both age 
groups had a tendency to use more ipsilateral paw in cylinder test, indicating a deficit of 
nigrostriatal dopaminergic system. In mice, LC injection in medial forebrain bundle (MFB) or 
SN has been shown to rapidly induce motor behavioral decline (Li et al. 2010; Bentea et al. 
2015), and similarly in rats, motor decline has been reported after MFB or SN injection (Vernon 
et al. 2011; Konieczny et al. 2014a). Interestingly, striatal injection of LC in rats did not cause 
behavioral decline in a study by (Lorenc-Koci et al. 2011).  
LC rapidly produced dopaminergic neurodegeneration in SN and depletion of striatal dopamine 
levels leading to motor behavioral deficits, which is an important aspect for a PD model. Our 
observations are similar to previous studies (Vernon et al. 2011; Bentea et al. 2015) which 
showed the maximal neurodegenerative effect of LC at one week after injection. In our study, 
significant TH positive cell loss was observed in SNc, but in our 10-day study the lesion did 
not markedly proceed to the striatum in the young mice when TH positive terminals were 
analysed. However, striatal dopamine and DOPAC levels were reduced by 55%, suggesting 
that dopamine synthesis is decreased although the TH protein is still present. This may suggest 
that TH has been inhibited or neuronal damage is still progressing at day 10, although in another 
study striatal dopamine and DOPAC levels did not decrease any further after 1 week (Bentea 
et al. 2015). However, the dose of LC may explain this difference; Bentea et al. used a 3 µg 
dose in mice, whereas in our studies the dose was 2 µg, and it is possible that with a lower dose 
the neuronal degeneration is still progressing. Slow progression of LC-induced pathology has 
 also been reported by Harrison et al. (2016) where they noticed a decrease in TH positive 
neurons of the ventral tegmental area 5 weeks after LC injection. Moreover, aSyn is known to 
inhibit TH activity (Perez et al. 2002; Lou et al. 2010), and we observed increased aSyn levels 
in the SN, suggesting a mechanism for reduced dopamine content in the striatum. When we 
investigated striatal TH ODs in young and adult mice, the TH loss seems to be greater in the 
adult mice, which supports the role of age as a factor for neurodegeneration. Although the 
number of adult mice was low in our study, the results suggest that it might increase the validity 
and translation of the results where the pre-clinical studies would be made in age-matched 
animals. Dopaminergic neurotransmission inhibits the GABAergic system, and when 
dopaminergic regulation is decreased in PD, GABAergic neurotransmission is enhanced (for 
review, see Galvan and Wichmann 2007). As presumed, in our study GAD expression was 
elevated in SNr, possibly contributing to a decrease of striatal dopamine. Increased GAD 
expression is also seen in earlier neurotoxin studies, where increased GABAergic activity 
(Wang et al. 2010) and GAD mRNA expression (Salin et al. 2002; Wang et al. 2010) in the 
lesion side in PD 6-OHDA rat model has been reported. In addition, LC is not a specific toxin 
for dopaminergic neurons, and increase in GAD may also propose that dopaminergic neurons 
are more sensitive for LC toxicity than GABAergic neurons in SN.  
Interestingly, we observed massive glial cell activation after LC injection. Glial activation is 
characteristic for PD and other synucleinopathies (McGeer et al. 1988; Gerhard et al. 2003; 
Braak et al. 2007; Stefanova et al. 2007; Iannaccone et al. 2013). Both astroglial and microglial 
cells were activated throughout the LC injected hemisphere and this indicates that LC, and 
possibly also increased aSyn protein accumulation, have activated a pro-inflammatory signal 
cascade leading to widespread activation of glial cells that may further enhance the 
neurodegeneration (Imamura et al. 2003; Gao et al. 2008; Kwon et al. 2008; Lee et al. 2010). 
Glial activation in the SN in the LC model has earlier been reported in mice (Li et al. 2010) but 
in the rat model no remarkable activation three weeks after injection was seen (McNaught et 
al. 2002). However, in the studies by Pienaar et al. (2015) and Elson et al. (2016), LC injection 
to rat SN caused significantly increased microglial cell activation in pedunculopontine nucleus 
that was accompanied by increased aSyn expression, supporting the spreading of aSyn 
pathology and glial activation after proteasome inhibition.  
Proteasome inhibition has been shown to inhibit GFAP expression (Middeldorp et al. 2009) 
and despite the widespread astrogliosis, we saw reduced GFAP-immunostaining around the 
injection site in the SN indicating that astrogliosis is a result of activated inflammatory 
 cascades, not only spread of the 1 ul volume. Unfortunately, we are not able to directly compare 
a difference in the amount of activation of neuroinflammation in the two age groups of mice 
because they were not stained and sections were not scanned simultaneously. However, based 
on immunostaining, more intense spreading of astrogliosis to striatum was seen in adult mice, 
suggesting that their nigrostriatal tract is more vulnerable for glial activation. In addition to glial 
activation, we also detected increased ubiquitin-positive immunostaining in astroglial and 
microglial cells after LC injection. Astroglial cells are also responsive for proteasomal deficits 
and develop protein aggregates but they are not as sensitive as neurons (Goldbaum et al. 2009) 
and usually protein aggregates are less abundant than in neurons (Wakabayashi et al. 2000; 
Braak et al. 2007). However, proteasomal inhibition can disrupt glial cells (Kwon et al. 2008; 
Middeldorp et al. 2009) leading to their dysfunction that further enhances neurodegeneration. 
aSyn can also be directly transferred from neurons to astroglia which leads to formation of 
inclusion bodies and activation of microglia by cytokines and chemokines (Lee et al. 2010). 
Our results further support this finding.  
Important for mimicking PD pathology, we observed increased aSyn immunostaining in the 
SN, supporting the role of proteasomes in aSyn accumulation and also the toxicity of aSyn to 
dopaminergic neurons. Recent studies have shown accumulation of phosphorylated aSyn in 
mice SN after LC injection (Bentea et al. 2015) in immunohistochemistry but also reduced 
soluble aSyn has been observed in rat (Lorenc-Koci et al. 2011) in Western blot. Although 
Lorenc-Koci et al (2011) did not measure the oligomeric forms of aSyn, the toxic species, it is 
likely that disturbed degradation of aSyn by blocking the proteasomes lead to increased 
concentration of aSyn which is a key factor to enhance the interaction between aSyn molecules, 
leading to aggregation of aSyn (Wood 1999). It remains a challenge to study aSyn protein 
aggregation in a mouse that does not have transgenic human aSyn, since there is a lack of decent 
and specific antibodies against mouse oligomeric or phosphorylated aSyn. 
 
Conclusions 
In this study we characterized various aspects of LC administration as a preclinical PD model 
and focused on studying the early changes (less than two weeks) occurring after injection. The 
presented LC mouse model very well establishes PD-like characteristics with motor 
disturbances, degeneration of TH positive neurons with dopamine loss, aSyn accumulation and 
neuroinflammation. In addition, although the number of adult mice in this study was low, our 
 results suggest that older mice were more sensitive for dopaminergic cell loss compared to 
young animals, supporting their use in the PD toxin models. In longer-term studies, it might be 
rational to scale down the dose to observe a milder and progressive phenotype and to study the 
effects in human aSyn expressing/overexpressing animals. Furthermore, it remains to be 
studied what would be the long-term effects of LC in terms of aSyn aggregate formation and 
possible recovery. This model is an interesting pre-clinical tool to be used for studying many 
types of treatment strategies against PD and also other diseases associated with protein 
clearance deficits and neuronal inflammation.  
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